Search filters

List of works by Julie Ledgerwood

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

scientific article published on 27 November 2019

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine — Preliminary Report

scientific article

A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes

scientific article published on 21 September 2016

A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial ⬇️

scientific article published on March 11, 2011

A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate ⬇️

scientific article published on August 19, 2010

A proof of concept for structure-based vaccine design targeting RSV in humans

scientific article published on 01 August 2019

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults

scientific article published on 27 October 2010

AS03-adjuvanted influenza vaccine in elderly people ⬇️

scientific article published on March 19, 2013

Activation Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory B cell Responses to Influenza Hemagglutinin

scientific article published on 23 July 2019

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial

scientific article published in June 2017

An mRNA Vaccine against SARS-CoV-2 - Preliminary Report

scientific article published on 14 July 2020

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

scholarly article by Nicole Doria-Rose published in 2021

Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial

scientific article published on 26 November 2020

Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial

scientific article published on 03 July 2019

Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection

scientific article published on 21 February 2017

Author Correction: Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses

scientific article published on 01 June 2019

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

scientific article

Brief Report: Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01

scientific article published on 01 April 2020

Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype ⬇️

scientific article

Chimpanzee Adenovirus Vector Ebola Vaccine — Preliminary Report

scientific article

Chimpanzee Adenovirus Vector Ebola Vaccine--Preliminary Report

scientific article published in August 2015

Circulating CXCR5⁺CD4⁺ T Follicular-Like Helper Cell and Memory B Cell Responses to Human Papillomavirus Vaccines

scientific article published on 2 September 2015

Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus

scientific article published in January 2014

Convergent Evolution in Breadth of Two VH6-1-Encoded Influenza Antibody Clonotypes from a Single Donor

scientific article published on 29 June 2020

Corrigendum: Protection against malaria at 1 year and immune correlates following PfSPZ vaccination

scientific article published in June 2016

Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions

scientific article published on 20 December 2020

Cutting Edge: Transcriptional Profiling Reveals Multifunctional and Cytotoxic Antiviral Responses of Zika Virus-Specific CD8 T Cells

article

DNA Priming Prior to Inactivated Influenza A(H5N1) Vaccination Expands the Antibody Epitope Repertoire and Increases Affinity Maturation in a Boost-Interval–Dependent Manner in Adults ⬇️

scientific article published on April 30, 2013

DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial ⬇️

scientific article published on April 8, 2013

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials ⬇️

scientific article published on 03 October 2011

DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial

scientific article published on 7 May 2015

DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial

scientific article published in PLoS ONE

DNA vaccines: a safe and efficient platform technology for responding to emerging infectious diseases

scientific article published on September 2009

Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality

scientific article published on 01 June 2020

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

scientific article published on 03 December 2020

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

scientific article

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants

scientific article

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

scientific article

Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial

scientific article published on 01 April 2020

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

scientific article published on 30 December 2020

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

scientific article

Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo

scientific article

Epitope-Specific Serological Assays for RSV: Conformation Matters

scientific article published on 23 February 2019

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

scientific article published on 28 July 2020

Filovirus emergence and vaccine development: A perspective for health care practitioners in travel medicine ⬇️

scientific article published on June 26, 2010

Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages.

scientific article published on 05 February 2014

Functional Profiling of Antibody Immune Repertoires in Convalescent Zika Virus Disease Patients

scientific article

Functional interrogation and mining of natively paired human VH:VL antibody repertoires

scientific article published on 8 January 2018

H5N1 Vaccine-Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem.

scientific article published on 15 June 2015

Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial

scientific article

Impact of viral attachment factor expression on antibody-mediated neutralization of flaviviruses

scientific article published on 10 January 2013

Influenza Virus H5 DNA Vaccination Is Immunogenic by Intramuscular and Intradermal Routes in Humans ⬇️

scientific article published on September 5, 2012

Lymph Node Activation by PET/CT Following Vaccination With Licensed Vaccines for Human Papillomaviruses

scientific article published on 10 March 2017

Mechanism and significance of cell type-dependent neutralization of flaviviruses

scientific article

Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 ⬇️

scientific article published on June 29, 2011

Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach

scientific article published on 31 August 2020

Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses

scientific article published on 11 February 2019

Multiplexed FluoroSpot for the Analysis of Dengue Virus- and Zika Virus-Specific and Cross-Reactive Memory B Cells

article

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011).

scientific article published on 22 October 2009

P14-12. Safety and tolerability of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular, subcutaneous and intradermal administration in healthy adults

scientific article published on 22 October 2009

P15-17. Social media as a tool for engaging and educating audiences around HIV vaccine research and clinical trial participation

scientific article (publication date: 2009)

P18-06. Increased HIV-specific immunity in HIV-infected individuals vaccinated with a DNA prime, rAd5 boost regimen

article

Phase 1 study of pandemic H1 DNA vaccine in healthy adults

scientific article

Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost

scientific article published on 11 August 2015

Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011)

scientific article

Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults

scientific article published on 03 April 2017

Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans

scientific article published on July 2017

Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera

scientific article

Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect ⬇️

scientific article published on April 30, 2013

Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses

scientific article (publication date: 2 February 2010)

Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans

scientific article published on 4 October 2017

Progress with PfSPZ Vaccine, a radiation attenuated Plasmodium falciparum sporozoite vaccine

scientific article published on 22 September 2014

Protection against malaria at 1 year and immune correlates following PfSPZ vaccination

scientific article (publication date: 9 May 2016)

Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine

scientific article

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

scientific article

Randomization to standard and concise informed consent forms: Development of evidence-based consent practices ⬇️

scientific article published on April 20, 2012

Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART

article

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

scientific article published on 29 September 2020

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)

scientific article

Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial

scientific article published on 15 April 2019

Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial

scientific article

Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial

scientific article

Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial

scientific article published on 18 September 2019

Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial

scientific article published on 28 August 2019

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.

scientific article published on 24 January 2018

Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial

scientific article published on 14 August 2014

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults

scientific article published on September 2015

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.

scientific article published on 14 November 2017

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

scientific article published on 4 December 2017

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study

article by Martin R Gaudinski et al published 2 March 2019 in The Lancet

Structural and molecular basis for Ebola virus neutralization by protective human antibodies

scientific article

The Zika virus envelope protein glycan loop regulates virion antigenicity

scientific article published on 2 January 2018

Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire

scientific article published on 12 March 2013

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, doub

scientific article

Use of Hemagglutinin Stem Probes Demonstrate Prevalence of Broadly Reactive Group 1 Influenza Antibodies in Human Sera.

scientific article

Use of low dose rVSV-ZEBOV: safety issues in a Swiss cohort

scientific article published on 3 August 2015

Vaccinate for the next H2N2 pandemic now.

scientific article

Vaccine development in the twenty-first century: changing paradigms for elusive viruses

scientific article

Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses

scientific article

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

scientific article published on December 2015

Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus

scientific article

Zika Virus Vaccine Development: Progress in the Face of New Challenges

article

Paulina is supported by:

About Paulina

Help